Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birabresib + Azacitidine in Newly Diagnosed AML
NCT02303782Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jan 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of birabresib in acute myeloid leukemia (AML) (2 arms), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicity occurrence and Complete Remission rate at Day 115. Planned start Jan 2015; status: withdrawn.
02
Drugs
birabresib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02303782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303782.